About Mynvax
Mynvax is a company based in Bengaluru (India) founded in 2017. Mynvax has raised $9.82 million across 5 funding rounds from investors including Kotak Mahindra Bank, Accel and LetsVenture. The company has 26 employees as of April 10, 2024. Mynvax offers products and services including Influenza Vaccine and COVID-19 Vaccine. Mynvax operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
- Headquarter Bengaluru, India
- Employees 26 as on 10 Apr, 2024
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Mynvax Private Limited
- Date of Incorporation 05 May, 2017
- Jurisdiction Bangalore, Karnataka, India
-
Annual Revenue
$1.32 M (USD)89.38as on Mar 31, 2023
-
Net Profit
-$859.54 K (USD)12.15as on Mar 31, 2023
-
EBITDA
-$2.09 M (USD)-48.8as on Mar 31, 2023
-
Total Equity Funding
$9.82 M (USD)
in 5 rounds
-
Latest Funding Round
$2.6 M (USD), Series A
May 24, 2024
-
Investors
Kotak Mahindra Bank
& 70 more
-
Employee Count
26
as on Apr 10, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Mynvax
Mynvax offers a comprehensive portfolio of products and services, including Influenza Vaccine and COVID-19 Vaccine.
Thermostable recombinant vaccine for influenza protection.
Efficacious thermotolerant vaccine against COVID-19 variants.
Funding Insights of Mynvax
Mynvax has successfully raised a total of $9.82M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $2.6 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Mynvax
Mynvax has secured backing from 71 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Kotak Mahindra Bank, Accel and LetsVenture.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Accel is recognized as a leading venture capital firm.
|
Locked | Locked | Locked | |
|
Private equity firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Venture capital fund focused on healthtech, biotech, and multiple sectors
|
Locked | Locked | Locked |
Investor details for Mynvax
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Mynvax
Investment portfolio details for Mynvax
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Mynvax
Detailed financials for Mynvax
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Mynvax Comparisons
Peer comparison for Mynvax
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Mynvax
Mynvax operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
Antiviral oral therapeutics are developed for infectious diseases and cancers.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| Locked | Locked | Locked |
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
Detailed competitors of Mynvax
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mynvax
Complete news archive for Mynvax
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mynvax
Mynvax was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Mynvax is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Mynvax is a funded company, having raised a total of $9.82M across 5 funding rounds to date.
As of Apr 10, 2024, the latest employee count at Mynvax is 26.
Annual revenue of Mynvax is $1.32M as on Mar 31, 2023.
Mynvax was established in 2017 in Bengaluru, India, within the biotechnology sector focused on vaccine development. Operations center on creating recombinant vaccines targeting the human influenza virus and SARS-CoV-2. Genetic engineering is applied to the receptor binding domain of the viruss spike glycoprotein, enabling attachment to ACE2 receptors in human respiratory cells. Research and production activities are conducted to address viral threats in this field.
Mynvax's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
Mynvax offers Influenza Vaccine and COVID-19 Vaccine.
Mynvax has 71 investors. Key investors include Kotak Mahindra Bank, Accel, LetsVenture, Italica, and 1Crowd.
The valuation of Mynvax is $17.63M as of Jul 2021.